Evidenze

Executive Summary

Evidenze is a Barcelona-based full-service CRO founded in 2018 that combines deep therapeutic expertise with digital technology solutions to accelerate clinical trials and optimize costs. Targeting biotech and small-to-medium pharma clients, the company positions itself as a 'full value CRO' covering the entire clinical research lifecycle. By integrating AI/ML tools into trial design, patient recruitment, and data analytics, Evidenze aims to differentiate from traditional CROs and capture market share in the rapidly evolving clinical research landscape. Its early-stage focus on digital innovation aligns with industry trends toward decentralized and tech-enabled trials, offering potential for scalable growth. Despite being a relatively young player, Evidenze has established a presence in Europe and is now seeking to expand its client base and service offerings. Key near-term catalysts include securing anchor partnerships with mid-size biotechs, rolling out proprietary digital platforms, and potentially entering the U.S. market through strategic collaborations. The company's profitability hinges on its ability to convert pilot projects into recurring revenue and to demonstrate measurable efficiencies for clients. With a lean operation and a technology-first approach, Evidenze is positioned to gain traction in a fragmented CRO market, though execution risks remain given competitive pressures and the need for sustained investment.

Upcoming Catalysts (preview)

• Q3 2026Major biotech partnership for a pivotal trial contract70% success
• Q2 2026Launch of AI-powered patient recruitment and retention platform80% success
• Q4 2026Expansion into the North American market via a U.S. office or acquisition50% success